MBCProject_0003_T2_RNA
— · A
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- A
- subtype
- A
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- WNT_BETA_CATENIN_SIGNALING+0.270
- ESTROGEN_RESPONSE_EARLY+0.240
- KRAS_SIGNALING_DN+0.230
- MYOGENESIS+0.230
- APICAL_JUNCTION+0.190
- HEDGEHOG_SIGNALING+0.190
- NOTCH_SIGNALING+0.190
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.160
- APICAL_SURFACE+0.150
- PANCREAS_BETA_CELLS+0.120
Top 10 suppressed
- PROTEIN_SECRETION-0.580
- E2F_TARGETS-0.520
- MTORC1_SIGNALING-0.510
- MYC_TARGETS_V1-0.510
- G2M_CHECKPOINT-0.480
- OXIDATIVE_PHOSPHORYLATION-0.420
- CHOLESTEROL_HOMEOSTASIS-0.330
- UNFOLDED_PROTEIN_RESPONSE-0.300
- HEME_METABOLISM-0.280
- COMPLEMENT-0.260
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-A7-A426-01A-22R-A24H-07 | — | A | 0.908 |
| 2 | SRR8613808 | — | D | 0.872 |
| 3 | R116 | — | — | 0.872 |
| 4 | TCGA-AC-A3W7-01A-11R-A22K-07 | — | A | 0.869 |
| 5 | MNG1258 | — | — | 0.865 |
| 6 | 9176b038-65e3-469d-a867-d99bc732e45d | — | — | 0.863 |
| 7 | TCGA-5L-AAT0-01A-12R-A41B-07 | — | A | 0.862 |
| 8 | TCGA-PE-A5DD-01A-12R-A27Q-07 | — | A | 0.861 |
| 9 | 12305e97-f72f-4de7-9735-4cdbecb60296 | — | — | 0.860 |
| 10 | SRR1313107 | — | F | 0.857 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 14 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| WNT_BETA_CATENIN_SIGNALING | 0.270 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.240 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.230 | Remibrutinib | — uncovered |
| MYOGENESIS | 0.230 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.190 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.190 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.190 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.160 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.150 | Temsirolimus | — uncovered |
| PANCREAS_BETA_CELLS | 0.120 | Cobimetinib | — uncovered |
| TGF_BETA_SIGNALING | 0.090 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.070 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.020 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.010 | Remibrutinib | — uncovered |